Merck’s COVID-19 Therapeutic Development Path Gets A Little Harder

Pharma Shelves One Drug Program, Narrows Another

 
• By Alaric DeArment
  
COVID-19 SARS,Coronaviridae , SARS-CoV, SARSCoV, virus 2020 , MERS-CoV ,chinese virus 2019-nCoV
Merck & Co. shelved its MRK-7110 COVID-19 program and is focusing on outpatients for molnupiravir • Source: Shutterstock

More from COVID-19

More from Scrip